GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 134 Note 48 : Financial instruments - Fair value and Risk Management A. Accounting classification and fair values The following table shows the carrying amounts and fair values of financial assets and financial liabilities including their levels presented below. ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Financial assets at amortised cost * Security Deposits 8,06.08 8,21.56 Margin money/ Deposit against bank guarantee 4,01.47 4,13.53 Trade receivables 215,60.46 99,80.12 Cash and cash equivalents 404,90.20 98,02.79 Bank balances other than Cash and cash equivalents 752,77.48 968,37.73 Interest accrued on deposits with bank 7,50.06 23,15.78 Receivable from group companies 11,38.56 7,30.82 Advances recoverable 31.65 44.62 Total financial assets 1404,55.96 1209,46.95 *Excludes investments in subsidiary Financial liabilities at amortised cost Borrowings 2.40 17.70 Other financial lease liabilities 34,60.26 41,66.30 Security deposits received 2,04.46 2,05.97 Payable to employees 126,97.57 95,55.20 Unclaimed dividends 19,86.36 20,44.34 Trade payables 446,32.86 354,18.67 Creditors for capital goods 2,17.03 24,03.59 Rationalisation relating to a manufacturing site 1,30.28 1,30.28 Other Payables 21,56.59 1,40.91 Total financial liabilities 654,87.81 540,82.96 B. Fair Value Hierarchy This section explains the judgements and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the Standalone Financial Statements. (a) Financial instruments that are recognised and measured at fair value To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting standard. Level 1 : It includes financial instruments measured using quoted prices Level 2 : The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.